

Product datasheet for **SR303935**

PYGL Human siRNA Oligo Duplex (Locus ID 5836)

Product data:

| | |
|---------------------|--|
| Product Type: | siRNA Oligo Duplexes |
| Purity: | HPLC purified |
| Quality Control: | Tested by ESI-MS |
| Sequences: | Available with shipment |
| Stability: | One year from date of shipment when stored at -20°C. |
| # of transfections: | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM). |
| Note: | Single siRNA duplex (10nmol) can be ordered. |
| RefSeq: | NM_001163940 , NM_002863 |
| UniProt ID: | P06737 |
| Synonyms: | GSD6 |
| Components: | PYGL (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 5836) Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol Included - SR30005, RNase free siRNA Duplex Resuspension Buffer - 2 ml |
| Summary: | This gene encodes a homodimeric protein that catalyses the cleavage of alpha-1,4-glucosidic bonds to release glucose-1-phosphate from liver glycogen stores. This protein switches from inactive phosphorylase B to active phosphorylase A by phosphorylation of serine residue 15. Activity of this enzyme is further regulated by multiple allosteric effectors and hormonal controls. Humans have three glycogen phosphorylase genes that encode distinct isozymes that are primarily expressed in liver, brain and muscle, respectively. The liver isozyme serves the glycemic demands of the body in general while the brain and muscle isozymes supply just those tissues. In glycogen storage disease type VI, also known as Hers disease, mutations in liver glycogen phosphorylase inhibit the conversion of glycogen to glucose and results in moderate hypoglycemia, mild ketosis, growth retardation and hepatomegaly. Alternative splicing results in multiple transcript variants encoding different isoforms.[provided by RefSeq, Feb 2011] |



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).